Brolucizumab Antibody

SKU: orb1944162

Description

Brolucizumab (DLX1008) is a high-affinity, single-chain anti-VEGF-A antibody fragment for research. It potently inhibits VEGF-A to suppress pathological angiogenesis and vascular permeability, supporting in vitro and in vivo studies in ophthalmology, particularly for neovascular age-related macular degeneration (AMD).

Research Area

Cardiovascular Research, Signal Transduction

Key Properties

• CAS Number: 1531589-13-5
• MW: ~150 kDa
• Purity: 95.00%
• Target: VEGFR

Bioactivity

• In Vivo:
  Brolucizumab (15 mg/kg, intravenous injection, five days a week) was used to treat mSLK-KSHV xenografts and the tumor growth in vivo was observed. Results: Brolucizumab slowed the growth of mSLK-KSHV xenograft tumors.
• In Vitro:
  Brolucizumab (2683 nM) inhibits VEGFR1 phosphorylation in VEGF-A112-induced U87MG human glioma cells and VEGFR2 phosphorylation in ZHE-483-2 GMECs.

Storage & Handling

• Storage: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

RTH258, ESBA 1008, DLX1008

Quick Database Links

Gene Symbol

VEGFR